Mandag, Lita B.
HRN: 12-11-79 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/28/2024
CO-AMOXICLAV 625MG (TAB)
01/28/2024
02/04/2024
ORAL
625mg
BID
BLEPHARITIS
Waiting Final Action
Indication: Empiric Type of Infection: Eye, Ear, Nose, Throat, & Mouth Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes